Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 9/20 | 0.43 |
| ▸ | CA2 | P00918 | 9/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | PYGB | P11216 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882333 | 1.00 | GSK3B (0.47) | GSK3BADKCA1CA2TSHR | |
| SCHEMBL6888305 | 0.90 | GSK3B (0.38) | GSK3BADKCA1CA2TSHR | |
| SCHEMBL11198199 | 0.86 | GSK3B (0.47) | GSK3BADKCA1CA2TSHR | |
| SCHEMBL3363495 | 0.86 | GSK3B (0.47) | GSK3BADKCA1CA2TSHR | |
| SCHEMBL5697577 | 0.86 | GSK3B (0.47) | GSK3BADKCA1CA2TSHR | |
| SCHEMBL6889028 | 0.86 | GSK3B (0.47) | GSK3BADKCA1CA2TSHR | |
| SCHEMBL4286250 | 0.86 | GSK3B (0.47) | GSK3BADKCA1CA2TSHR | |
| SCHEMBL3718127 | 0.86 | GSK3B (0.47) | GSK3BADKCA1CA2TSHR | |
| SCHEMBL6887314 | 0.85 | GSK3B (0.47) | GSK3BADKCA1CA2TSHR | |
| SCHEMBL6887317 | 0.85 | GSK3B (0.49) | GSK3BADKCA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668023-A1 | B-L-NUCLEOSIDES AND USE THEREOF AS PHARMACEUTICAL AGENTS FOR TREATING VIRAL DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005026186-A1 | Β-L-NUCLEOSIDES AND USE THEREOF AS PHARMACEUTICAL AGENTS FOR TREATING VIRAL DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2005-03-24 | — | — | WO | disclosed |